PresseKat - Santhera to Report Half-Year 2016 Financial Results on Tuesday, September 6, 2016

(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera to Report Half-Year 2016 Financial Results on Tuesday, September 6,
2016
. Verarbeitet und übermittelt durch Nasdaq Corporate Solutions.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Source: Globenewswire

Liestal, Switzerland, August 29, 2016 - Santhera Pharmaceuticals (SIX: SANN), a
Swiss specialty pharmaceutical company, will announce the financial results for
the first half-year 2016 on Tuesday, September 6, 2016, at 7:00 am CET. An
Investor Conference Call with Thomas Meier, PhD, CEO of Santhera
Pharmaceuticals, will be held on the same day at 5:00 pm CET.

Participants can call the following numbers 10-15 minutes before Conference's
schedule (no code needed):
+41 (0)58 310 50 00 (Europe)
+44 (0)203 059 58 62 (UK)
+1 (1)631 570 5613 (USA)

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan mitochondrial and neuromuscular diseases.
Santhera's lead product Raxone® is authorized in the European Union, Norway,
Iceland and Liechtenstein for the treatment of Leber's hereditary optic
neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication
for Raxone(®), Santhera has filed a Marketing Authorization Application (MAA) in
the European Union. Santhera develops Raxone(®) in a third indication, primary
progressive multiple sclerosis (PPMS), and omigapil for congenital muscular
dystrophy (CMD), all areas of high unmet medical need. For further information,
please visit the Company's website www.santhera.com.
Raxone(®) is a trademark of Santhera Pharmaceuticals.

For further information, contact:
Thomas Meier, PhD, Chief Executive Officer Christoph Rentsch, Chief

Financial Officer
Phone +41 61 906 89 64                                        Phone
+41 61 906 89 65
thomas.meier(at)santhera.com
christoph.rentsch(at)santhera.com

Daniel Piller, Head Communications
Phone +41 61 906 89 26
daniel.piller(at)santhera.com

US investor contact                                        US Public Relations
contact
Hans Vitzthum, LifeSci Advisors, LLC                    Deanne Eagle, Planet
Communications
Phone +1 212 915 2568                                        Phone
+1 917 837 5866
hans(at)lifesciadvisors.com
deanne(at)planetcommunications.nyc

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.

# # #

News Release Schedule HY Results:
http://hugin.info/137261/R/2037721/759305.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire

Liestal

Wirtschaft (allg.)

Santhera to Report Half-Year 2016 Financial Results on Tuesday, September 6, 2016

Liestal

Wirtschaft (allg.)

Start der Phase-III-Studie mit Catena®/Sovrima® (Idebenone) in Duchenne-Muskel ...

Santhera und Biovail schliessen Lizenzvertrag zur Entwicklung und Vermarktung vo ...

Santhera übernimmt Juvantia und sichert sich alle Rechte an JP-1730/Fipamezole ...

Alle Meldungen von Santhera Pharmaceuticals Holding AG